X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (2) 2
aged (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cells (2) 2
etoposide (2) 2
female (2) 2
humans (2) 2
male (2) 2
middle aged (2) 2
salvage chemotherapy (2) 2
sensitivity (2) 2
topotecan (2) 2
treatment outcome (2) 2
13-cis-retinoic acid (1) 1
acute myeloblastic-leukemia (1) 1
acute myelogenous leukaemia (1) 1
acute myeloid-leukemia (1) 1
acute-leukemia (1) 1
aged, 80 and over (1) 1
all-trans retinoic acid (1) 1
all-trans retinoid acid (1) 1
all‐trans retinoic acid (1) 1
aml blasts (1) 1
antigens, neoplasm (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
apoptosis (1) 1
bcl- 2 (1) 1
bcl-2 (1) 1
bcl‐2 (1) 1
camptothecin (1) 1
cancer (1) 1
chemotherapy (1) 1
cytarabine - administration & dosage (1) 1
dna topoisomerase i (1) 1
dna topoisomerases, type i - drug effects (1) 1
dna topoisomerases, type i - genetics (1) 1
dna topoisomerases, type i - metabolism (1) 1
dna topoisomerases, type ii - drug effects (1) 1
dna topoisomerases, type ii - genetics (1) 1
dna topoisomerases, type ii - metabolism (1) 1
dna, neoplasm - drug effects (1) 1
dna, neoplasm - metabolism (1) 1
dna-binding proteins (1) 1
etoposide - administration & dosage (1) 1
etoposide - adverse effects (1) 1
etoposide - therapeutic use (1) 1
evaluation (1) 1
expression (1) 1
genes, bcl-2 - genetics (1) 1
hematology (1) 1
i-inhibitor topotecan (1) 1
induction (1) 1
isoenzymes - drug effects (1) 1
isoenzymes - genetics (1) 1
isoenzymes - metabolism (1) 1
leukemia, myeloid, acute - drug therapy (1) 1
leukemia, myeloid, acute - genetics (1) 1
leukemia, myeloid, acute - pathology (1) 1
lymphoma, non-hodgkin - drug therapy (1) 1
lymphoma, non-hodgkin - enzymology (1) 1
mechanism (1) 1
myelodysplastic syndrome (1) 1
non-hodgkin lymphoma (1) 1
non-hodgkin's lymphomas (1) 1
non‐hodgkin lymphoma (1) 1
oncology (1) 1
phase-i (1) 1
proliferation (1) 1
proto-oncogene proteins c-bcl-2 - metabolism (1) 1
recurrence (1) 1
replication (1) 1
rna, messenger - drug effects (1) 1
rna, messenger - metabolism (1) 1
survival analysis (1) 1
topoisomerase-dna complexes (1) 1
topoisomerase–dna complexes (1) 1
topotecan - administration & dosage (1) 1
topotecan - adverse effects (1) 1
topotecan - therapeutic use (1) 1
tretinoin - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2001, Volume 91, Issue 3, pp. 463 - 471
BACKGROUND. Topotecan, a topoisomerase I inhibitor, acts by stabilizing the topoisomerase DNA cleavage complex. Etoposide, a topoisomerase II inhibitor,... 
Non-Hodgkin lymphoma | Etoposide | Topotecan | Topoisomerase-DNA complexes | Salvage chemotherapy | CELLS | MECHANISM | SENSITIVITY | non-Hodgkin lymphoma | PROLIFERATION | CANCER | I-INHIBITOR TOPOTECAN | ACUTE-LEUKEMIA | salvage chemotherapy | REPLICATION | ONCOLOGY | topoisomerase-DNA complexes | CAMPTOTHECIN | etoposide | PHASE-I | topotecan | DNA, Neoplasm - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma, Non-Hodgkin - enzymology | RNA, Messenger - metabolism | DNA Topoisomerases, Type I - drug effects | Isoenzymes - metabolism | Adult | Female | DNA-Binding Proteins | Lymphoma, Non-Hodgkin - drug therapy | RNA, Messenger - drug effects | DNA Topoisomerases, Type II - metabolism | Antigens, Neoplasm | Etoposide - adverse effects | DNA Topoisomerases, Type I - metabolism | Isoenzymes - genetics | DNA Topoisomerases, Type I - genetics | Topotecan - adverse effects | Etoposide - administration & dosage | Etoposide - therapeutic use | Treatment Outcome | Topotecan - therapeutic use | DNA, Neoplasm - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | DNA Topoisomerases, Type II - drug effects | Topotecan - administration & dosage | DNA Topoisomerases, Type II - genetics | Aged | Isoenzymes - drug effects | Evaluation | Non-Hodgkin's lymphomas | Antineoplastic agents | DNA topoisomerase I
Journal Article
Cancer, ISSN 0008-543X, 02/2001, Volume 91, Issue 3, pp. 463 - 471
BACKGROUND Topotecan, a topoisomerase I inhibitor, acts by stabilizing the topoisomerase DNA cleavage complex. Etoposide, a topoisomerase II inhibitor,... 
topoisomerase–DNA complexes | salvage chemotherapy | non‐Hodgkin lymphoma | etoposide | topotecan
Journal Article
Blood, ISSN 0006-4971, 2000, Volume 96, Issue 11, p. 380
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.